Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial Results
Continued execution across all programs, including positive results up to nine months from APG777 Phase 1 trial that continue to support ...
Promising Advancements and Strategic Positioning Propel Apogee Therapeutics, Inc. to a Buy Rating
TD Cowen analyst Tyler Van Buren has maintained their bullish stance on APGE stock, giving a Buy rating on October 28. Tyler Van Buren has ...